|
 |
ZavescaThis page contains recent news articles, when available, and an overview of Zavesca but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Actelion revealed last month that the Food and Drug Administration has granted priority status to its new drug application for Zavesca (miglustat). Zenopa W zaklÄ™tym krÄ™gu choroby Wojtusia tracimy nadziejÄ™ - Dec 16, 2009 WojtuÅ› potrzebuje specjalistycznej kosztownej diety, leku Zavesca i badania genetycznego. DziÅ› nadal brakuje nam pieniÄ™dzy na lek, który ciÄ…gle ma bardzo ... Wiadomosci 24 Actelion Pharmaceuticals Ltd (CH) - Actelion announces 9-month financial ... - Oct 21, 2009 In local currencies, Zavesca® sales increased by 33 percent. Zavesca® is commercially available in over 35 countries including the United States and most ... PharmaLive.com (press release) Tracleer drives Actelion sales up 22% - Oct 20, 2009 Of the firm's other products, Ventavis (iloprost), an inhaled therapy for the treatment of PAH, leapt 57.5% to 101.6 million francs, while sales of Zavesca ... Pharma Times ChcÄ™ żyć - pomóż mi! - Nov 12, 2009 WojtuÅ› potrzebuje leku ZAVESCA. Cena leku to 138$ za kapsuÅ‚kÄ™. ChÅ‚opiec potrzebuje dwóch kapsuÅ‚ek dziennie. Czy uda nam siÄ™ uzbierać kwotÄ™ niezbÄ™dnÄ… na ... Wiadomosci 24 WojtuÅ› Sekulski odwiedziÅ‚ elblag24 - Oct 20, 2009 Jedynym medykamentem, który może pomóc Wojtkowi to ZAVESCA. Lek ten podawany jest chorym na Niemanna Picka. Zavesca jest wskazana do stosowania w leczeniu ... Wiadomosci 24 Actelion steigert Neunmonatsumsatz - Guidance bestätigt (AF) - Oct 19, 2009 Der Umsatz von Zavesca erreichte 38,3 Mio CHF (+33% in LW). Das Medikament wird in über 35 Ländern vermarktet. Für Zavesca werde in den USA derzeit eine ... Handelszeitung Online Klub Mimoza - Wojtusiowi - Nov 5, 2009 ZamknÄ…Å‚ siÄ™ w sobie, a kontakt z 6-latkiem jest ograniczony. jedynym antidotum ratujÄ…cym chÅ‚opca jest lek Zavesca, który kosztuje 138 dolary za jednÄ… ... Wiadomosci 24 RPT/PRÉVISIONS/Actelion T3: bénéfice net attendu entre 97,4 et 131,4 mio CHF - Oct 19, 2009 Pour ce qui est de Zavesca, on peut prévoir une augmentation des ventes à cause de problèmes de livraison d'un concurrent et on espère aussi des ... Romandie.com DOENÇAS RARAS - Oct 20, 2009 Prefeitura de Fortaleza, a suspensão do fornecimento do remédio Zavesca para uma paciente da Capital, de 21 anos, portadora de doença neurodegenerativa. ... Diário do Nordeste (Assinatura) 供应告急 åœ¨ç ”æˆˆè°¢ç—…è?¯ç¼ºå¤±æˆ?为焦点 - Oct 28, 2009 ...对那些ä¸?能è€?å?—酶替代治疗方法的患者æ?¥è¯´ï¼ŒActelion拥有一å?ªç§°ä¹‹ä¸ºç¾Žæ ¼é²?特（Miglustatã€?Zavesca）的è?¯ç‰©ï¼Œä½†æ˜¯è¿™å?ªè?¯ç‰©çš„副作用é?žå¸¸ä¸¥é‡?。 å?¥èµžå…¬å?¸å°†ä¸?å?¯èƒ½é•¿æœŸç‹¬å? ... 慧聪网 Actelion's Zavesca receives negative opinion for new indication from... - Oct 19, 2007 ZURICH (Thomson Financial) - Actelion's Zavesca has received a negative opinion for an additional indication from the Committee for Medicinal Products for ... Forbes Actelion pulls application for new Zavesca use - Feb 25, 2008 LONDON, Feb 25 (Reuters) - Swiss biotechnology company Actelion (ATLN.VX) has withdrawn its application for approval for a new use of its Zavesca drug, ... Reuters Zavesca may lose DOH funding - Nov 5, 2007 By Angelica Oung. Patients suffering from a rare degenerative brain disease might soon lose funding for an expensive drug that a leading neurologist says ... Taipei Times - Taipei Times … and UCB Enter Into Assignment and License Agreement for Zavesca --... - Nov 17, 2005 We are also committed to fully exploring the medical benefit Zavesca(r) might ... In addition, the ability of Zavesca(r) to cross the blood-brain barrier ... primezone.com Miglustat (Zavesca(R)) Receives Positive Opinion From The CHMP For … - Dec 24, 2008 Actelion Ltd (SIX: ATLN) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension of ... Medical News Today - Medical News Today (press release) One-Year Results On The Use Of Miglustat (Zavesca®) In Niemann-Pick … - Aug 22, 2007 Actelion Ltd (SWX: ATLN) announced the online publication in "The Lancet Neurology" of the one-year results from a randomized controlled study evaluating ... Medical News Today - Medical News Today (press release) One-Year results on the use of miglustat (Zavesca®) in Niemann-Pick … - Sep 10, 2007 ALLSCHWIL, SWITZERLAND – 30 August 2007 – Actelion Ltd (SWX: ATLN) announced today the online publication in “The Lancet Neurology “ of the one-year results ... Healthcare Republic - Healthcare Republic … Prolong Lives of Tay-Sachs Babies; Trial of Zavesca, Studied for... - Aug 5, 2005 Drug May Prolong Lives of Tay-Sachs Babies; Trial of Zavesca, Studied for Older Patients, Is First To Involve Infants ... find Forward articles. Pay-Per-View - Forward - HighBeam Research One-Year Results on the Use of Miglustat -- Zavesca -- in Niemann... - Oct 26, 2005 ALLSCHWIL, Switzerland, Oct. 26, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today a poster presentation at the annual ... primezone.com … : CHMP issues negative opinion on Zavesca;Wyeth CEO discusses the … - Oct 19, 2007 ...> The Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the extension of indication on the use of Actelion's Zavesca. ... FierceBiotech Tay-Sachs Disease; Zavesca trial in late onset Tay-Sachs disease … - Jan 17, 2005 2005 JAN 17 - (NewsRx.com & NewsRx.net) -- Actelion Ltd (ATLN) announced that the pivotal study evaluating safety and efficacy of miglustat (Zavesca) in ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Tay-Sachs Disease; Zavesca trial in late onset Tay-Sachs disease … - Jan 21, 2005 2005 JAN 21 - (NewsRx.com & NewsRx.net) -- Actelion Ltd (ATLN) announced that the pivotal study evaluating safety and efficacy of miglustat (Zavesca) in ... Pay-Per-View - Genomics & Genetics Weekly - Factiva, from Dow Jones Tay-Sachs Disease; Zavesca trial in late onset Tay-Sachs disease … - Jan 22, 2005 2005 JAN 22 - (NewsRx.com & NewsRx.net) -- Actelion Ltd (ATLN) announced that the pivotal study evaluating safety and efficacy of miglustat (Zavesca) in ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Actelion: Miglustat/Zavesca erhält pos. EU-Empfehlung für Niemann... - Dec 19, 2008 Allschwil (AWP) - Die Actelion hat vom europäischen Ausschuss für Humanarzneimittel (European Committee for Medicinal Products for Human Use - CHMP) einen ... Handelszeitung Online ZAVESCA救退化醫師：沒更好的藥 - Nov 4, 2007 ...胡務亮強調，「ZAVESCAã€?在臨床上確實讓「尼曼匹克症ã€?患者å?œæ¢é€€åŒ–，甚至在å?žåš¥å›°é›£ã€? 腦部退化的症狀ç?²å¾—改善，是治療的唯一藥物，沒有其他更好的替代藥物。 ... è‡ªç”±æ™‚å ± Menina de 3 anos fica sem remédio de R$ 17 mil - May 16, 2008 O medicamento Zavesca (miglustate) é a única forma conhecida para tratamento da enfermidade, segundo a Secretaria de Saúde da Bahia. De acordo com Carvalho, ... G1.com.br GlobeNewswire, Inc. - News Room - Feb 24, 2005 In 2004, Zavesca(r) sales were CHF 6.1 million (2003: CHF 0.7 m). Zavesca(r) became commercially available in the United States in early 2004. ... primezone.com Tay-Sachs Drug Trial Yields 'Neutral' Results - Aug 25, 2006 According to Crawford, Actelion, which produces Zavesca, will not seek FDA approval ... However, the hope was that Zavesca would stop or at least slow the ... Forward Accord pour l'accès au traitement par Zavesca pour les patients... - Feb 28, 2006 Le ZAVESCA®, nom commercial du miglustat, est un produit qui a reçu une Autorisation de Mise sur le Marché par l'Agence Européenne du Médicament (EMEA) en ... Association Vaincre les Maladies... DOH to hold meeting on drug funding - Nov 8, 2007 Meanwhile, Hu said that from his clinical experience, Zavesca helps halt the pace of ... Zavesca costs roughly NT$320000 per patient per month. ... China Post Zavesca: une indication pour la maladie de Tay-Sachs ? - Feb 28, 2006 Décidément le miglustat, commercialisé actuellement sous le nom ZAVESCA®, semble présenter des ouvertures thérapeutiques pour nombre de maladies lysosomales ... Association Vaincre les Maladies... 國å?¥å±€ï¼šå°¼æ›¼åŒ¹å…‹ç—‡æ‚£è€…臨床試驗ä¸?æ–·è—¥ - Mar 29, 2008 ...（ä¸å¤®ç¤¾è¨˜è€…陳清芳å?°åŒ—二å??ä¹?日電）衛生署國民å?¥åº·å±€å‰¯å±€é•·å?³ç§€è‹±ä»Šå¤©è¡¨ç¤ºï¼Œåœ¨ä»Šå¹´ 底之å‰?，罕病「尼曼匹克症ã€?患者ä¸?用擔心臨床試驗用藥ZAVESCA會斷藥，一年五ä½?患者 ... ntdtv.com Début de l'essai clinique Sanfilippo (MPS III) avec Miglustat (Zavesca... - Jan 17, 2007 L'objectif principal est d'évaluer si le traitement par Zavesca® des malades permet d'améliorer, ou de stabiliser, leurs troubles du comportement et leur ... Association Vaincre les Maladies... Vaincre les maladies lysosomales: Forum - Dec 22, 2008 Par contre, as-tu acceptée le traitement par le Zavesca? Comment se porte Lizzie ? le supporte-t-elle bien ? Tu peux nous joindre sur tél port; Nous pensons ... Association Vaincre les Maladies... å°?尼曼匹克症用藥ä¸?å†?ç?²å¾—補助一事--罕病基金會與尼曼匹克症è?¯èª¼æœƒè?¯å?ˆ … - Nov 7, 2007 ...本會在2006å¹´9月得知å?°å¤§åŸºå› 醫å¸éƒ¨ç ”究團隊é‡?å°?ZAVESCA治療尼曼匹克症已進行將近一 ... é‡?å°?還在臨床試驗階段的ZAVESCA治療尼曼匹克症計畫，經é?Žå°‡è¿‘一年來多次的討論 ... 公民新è?ž Vaincre les maladies lysosomales: Forum - May 6, 2008 Pendant 1 an, il a pris du Zavesca (arrêté en juillet 2007). Je sais que ce n'est pas simple et que chaque cas est différent ! ... Association Vaincre les Maladies... ФинанÑ?овые новоÑ?ти архив Actelion не Ñ?могла получить разрешение - Oct 19, 2007 ЕвропейÑ?кие регулирующие органы уже одобрили применение Zavesca при лечении болезни Гоше, однако компаниÑ? Actelion планирует получить разрешение на ... K2Kapital Actelion Announces Half-Year Financial Results 2005 - Jul 28, 2005 Zavesca(r) continues to add to top line Zavesca(r) sales contributed in the first ... Zavesca(r) is commercially available in the United States and in most ... primezone.com Actelion Announces First Quarter Results 2006 - Apr 20, 2006 In the first quarter of 2006, Zavesca(r) sales reached CHF 5.4 million (Q1 ... On a quarter-to-quarter basis, Zavesca(r) sales increased by 17 percent (Q4 ... primezone.com Actelion Announces 9-Month Results for 2005 - Oct 19, 2005 Zavesca(r) sales in the approved indication type 1 Gaucher disease contributed in ... Zavesca(r) is commercially available in the United States and in most ... primezone.com Actelion Announces Half Year Financial Results 2006 - Jul 20, 2006 Zavesca(r) sales contributed in the first half of 2006 CHF 11.6 million to ... Zavesca(r) is commercially available in the United States and in most ... primezone.com Actelion Announces 9-Month Results for 2006 - Oct 19, 2006 Zavesca(r) sales in the approved indication type 1 Gaucher disease contributed in ... Zavesca(r) is commercially available in the United States and in most ... primezone.com Actelion Announces Full Year 2005 Financial Results - Feb 23, 2006 Zavesca(r) sales contributed CHF 14.4 million (FY 2004: CHF 6.1 m) in 2005. On a quarter-to-quarter basis, Zavesca(r) revenues increased. primezone.com Boy, 2, Suffers From Rare Children's Alzheimer's Condition - May 9, 2008 Addi and Cassi are a part of a clinical drug trial for Zavesca. The girls take Zavesca in combination with a low dose of ibuprofen and curcumin, ... FOXNews AT ALL COSTS A CHILD'S DISEASE, A FAMILY'S SACRIFICE - Aug 8, 2006 That was when Emily had had just less than a month on Zavesca, ... Zavesca is approved for Gaucher's disease, a condition with some similar symptoms. ... $3.95 - Modesto Bee - NewsBank France's LEEM launches orphan drug campaign. - Jul 2, 2007 As the Zavesca incident confirmed, the demand for solutions to rare diseases is considerable, especially in cases involving diseases that afflict children. ... $9.94 - Pharma Marketletter - Alacra Store Améliorations cliniques dans la maladie de Niemann-Pick de type C … - Oct 4, 2007 Le Zavesca® est une molécule inhibant la première étape de la synthèse des ... Déjà prescrit dans la maladie de Gaucher, le zavesca® est capable d'atteindre ... Association Vaincre les Maladies... GlobeNewswire, Inc. - News Room - Apr 21, 2005 In the first quarter of 2005, Zavesca(r) sales reached CHF 2.4 million. ... On a quarter-to-quarter basis, Zavesca(r) sales increased by 14 percent (Q4 ... primezone.com … Européenne du Médicament pour l'extension de l'indication du Zavesc... - Nov 8, 2007 Suite à l'essai clinique du Zavesca® dans la maladie de Niemann-Pick C, ... En conclusion, le CHMP estime que les bénéfices du Zavesca® dans le traitement ... Association Vaincre les Maladies... Girl's family hoping for a cure - Apr 6, 2008 Mindy takes an experimental drug called Zavesca, which is her best hope. It is no cure, but perhaps it can prolong her life. ... MLive.com Donations tie drug firms and nonprofits: Many patient groups reveal... - May 28, 2006 In contrast, the foundation took nothing from Actelion Pharmaceuticals US Inc., of San Francisco, maker of a second-line treatment, Zavesca, to be used when ... Free with registration - Philadelphia Inquirer - AccessMyLibrary.com Donations link drug firms to nonprofit patient groups. - Jun 8, 2006 In contrast, the foundation took nothing from Actelion Pharmaceuticals US Inc., of San Francisco, maker of a second-line treatment, Zavesca, to be used when ... Free with registration - Philadelphia Inquirer - AccessMyLibrary.com Actelion starts phase II tests on miglustat for cystic fibrosis... - Sep 28, 2007 Zavesca, in the form of 100 mg of miglustat in capsules, is already approved in the EU and US as an oral treatment for type 1 Gaucher disease. Forbes Two New Gaucher Meds on Horizon - Aug 22, 2007 A similar medicine, called miglustat and marketed under the brand name Zavesca, has been available for several years, but is prescribed only to patients who ... Forward Q4 2005 Actelion Earnings Conference Call - Part 1. - Feb 23, 2006 If we change gears a little bit and look at Zavesca, our second product where we are still in the process of building a brand, very satisfactory growth ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Actelion Hosts its 3rd Research and Development Day - Sep 8, 2005 Line-extension studies for our two marketed products Tracleer(R) (bosentan) and Zavesca(R) (miglustat) will report data in short order until year-end. ... primezone.com Czy NFZ da nadziejÄ™ Kamilowi? - Oct 15, 2007 Ostatnio zaczęły siÄ™ pojawiać informacje, że lek o nazwie Zavesca, stosowany w chorobie genetycznej Gochera może pomagać również w chorobie Niemanna-Picka. ... Gazeta.pl - Gazeta.pl Q1 2005 Actelion Earnings Conference Call - Final. - Apr 21, 2005 Then following the reporting of 3 phase III studies with Zavesca in 3 different lipid-storage diseases the year end will be dominated by preliminary ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Stem cells have multiple brain benefits - Mar 12, 2007 Zavesca (miglustat) is now marketed by Actelion and is approved to treat Gaucher's disease - another disease caused by the build up of lipids. ... DrugResearcher.com Comment le miglustat agit contre la mucoviscidose - Oct 1, 2007 Autre avantage, cette molécule peut être administrée oralement, et surtout, elle est déjà utilisée, sous l'appelation Zavesca, dans le traitement d'une ... 20minutes.fr Article: Jazzman plays liturgy with a groove - Cleveland Jewish News... - Feb 24, 2006 ...says Shapiro, associate professor of neurology at ... Zavesca will slow down the course of LOTS, Shapiro says. Zavesca, which has not yet been ... ... Pay-Per-View - Cleveland Jewish News - HighBeam Research Article: Words of encouragement Internet blogs let family, friends... - Jul 13, 2005 Article: Actelion's Zavesca cleared for NPC.(Niemann-Pick ... ... Article: CHMP OKs Actelion's Zavesca for NPC.(Committee for Medicinal ... ... Pay-Per-View - Daily Herald - HighBeam Research Maladie de Sanfilippo - Essais cliniques aux HCL - L'information... - Jun 18, 2007 «L'essai clinique pour évaluer l'action du médicament Zavesca auprès de 25 enfants souffrant de la maladie de Sanfilippo ira à son terme et selon les ... Rhône-Alpes-Santé.com Panacos Appoints Dr. Tom Lategan, Vice President of Regulatory... - Feb 14, 2007 Also at Actelion, he drove the approval of ZAVESCA in the US after an unsuccessful ... TRACLEER and ZAVESCA are registered trademarks of Actelion ... Free with registration - Business Wire - AccessMyLibrary.com Drug Maker Stays Close to Doctors and Patients - Mar 16, 2008 The only other drug approved in this country and overseas for Gaucher disease is Zavesca, sold by the Swiss company Actelion. It is approved, though, ... New York Times Two products fuelling Actelion's growth spurt - Mar 2, 2007 The company's other drug, Zavesca, is an enzyme replacement therapy for another rare condition, the inherited Gaucher's disease caused by a genetic fault. ... Pharmafocus Article: NEWS AND ADVANCES IN BRIEF - Forward | HighBeam … - Aug 5, 2005 Tay-Sachs with the drug Zavesca, the trial was scheduled to last one year, ... Zavesca, also known as OGT918 or miglustat, works as a substrate inhibitor ... Pay-Per-View - Forward - HighBeam Research Actelion's R&D day: eight compounds in pipeline.(Brief Article) - Sep 19, 2005 Line-extension studies for our two marketed products Tracleer and Zavesca will report data in short order until year-end. Over the coming 18 months, ... $4.95 - Pharma Marketletter - ECNext The most common genetic disease you've never heard of; As many as 1 … - Sep 9, 2005 An oral medication, Zavesca, is available for those who cannot ... European studies have shown Zavesca is effective in Gaucher disease, another lipid ... Pay-Per-View - Cleveland Jewish News - HighBeam Research Olhão.com - O Portal de Guarulhos - Feb 13, 2006 Para sobreviver, o garoto precisa tomar, continuamente, o medicamento Miglustat (Zavesca), produzido por um laboratório dos Estados Unidos. ... Olhão NeurAxon Appoints Thomas Lategan, DPhil as Vice President of - Sep 16, 2008 He also drove approval of Zavesca(R) in the US following its unsuccessful application by a previous sponsor. From 1997 to 2000, Dr. Lategan held the ... Bloomberg Bloomberg Printer-Friendly Page - Jun 1, 2008 ...a chronic, life-threatening disorder which severely compromises the function of the lungs and heart, Zavesca (miglustat), a small-molecule oral therapy ... Bloomberg Brussels shares higher late morning; Agfa plummets on disappointing... - Nov 17, 2005 Earlier, the pharmaceutical company said it has signed a licence agreement for Switzerland's Actelion to manufacture and supply Gaucher disease drug Zavesca ... Forbes France Telecom Dips on Lowered Outlook - Oct 27, 2005 The company's approved Gaucher treatment Zavesca fails to substantially improve symptoms of a rare genetic disease called Niemann Picl Type C, a 29-patient ... BusinessWeek EU backs Gilead once-daily HIV pill, other drugs - Oct 18, 2007 VX) for a new use of its established medicine Zavesca in treating Niemann-Pick type C disease, an inherited neurodegenerative disease of childhood and ... Reuters The drug buying time for children - Nov 18, 2005 But then the Sixsmiths were offered a glimmer of hope, a new drug called miglustat or Zavesca, which was being used to treat Gaucher's Disease - an ... BBC News Un nouvel espoir pour les patients - Jun 23, 2008 Le miglustat est déjà commercialisé, sous le nom Zavesca en France, pour le traitement d'une maladie génétique rare, la maladie de Gaucher. ... nouvelobs.com Actelion bleibt auf starkem Wachstumskurs - Jul 20, 2006 Bereits verdoppelt wurden im ersten Halbjahr die Verkäufe des Mittels Zavesca auf 11,6 Mio. Franken. Die Erwartungen fürs ganze Jahr hat Actelion deutlich ... NZZ Online European Stocks Decline; HSBC, Commerzbank, AstraZeneca Drop - Oct 19, 2007 Switzerland's largest biotechnology company failed to win the backing of a European Union panel on the proposed use of its Zavesca drug for treating a fatal ... Bloomberg L'Etat doit-il prendre en charge les recherches sur les maladies … - Jun 12, 2007 Une étude sur l'efficacité d'un médicament (le Zavesca) pour ralentir les symptômes du syndrome de San Filippo, une maladie orpheline, risque d'être ... 20minutes.fr le Parisien - Archives Actualité - Archives - 01/01/1970 - Jun 12, 2007 Autre maladie lysosomale : la maladie de Gaucher , pour laquelle le miglustat (Zavesca) actuellement testé sur les enfants San Filippo est utilisé. ... Le Parisien AKTIEN SCHWEIZ/Verlauf: Eurex-Verfall ohne grosse Impulse - ABB … - Dec 19, 2008 Unternehmen hat einen positiven Bescheid des europäischen Ausschusses für Humanarzneimittel für eine Indikationserweiterung von Zavesca erhalten. ... Handelszeitung Online AKTIEN SCHWEIZ/Vorbörse: Schwächer - Vorgaben belasten - ABB im … - Dec 19, 2008 Das Unternehmen erhielt vom europäischen Ausschuss für Humanarzneimittel einen positiven Bescheid für eine Indikationserweiterung von Miglustat/Zavesca. ... Handelszeitung Online Economie - Détail d'un article - Feb 26, 2005 Après son premier bénéfice en 2004, le groupe bâlois table d'ici 2009 sur des ventes de 950 millions pour Tracleer et de 50 millions pour Zavesca. ... L'Agefi - L'Agefi (Abonnement) Chancen und Risiken nahe beieinander - Jul 1, 2008 Die restlichen 10% steuern die Präparate Ventavis und Zavesca bei (siehe Kasten). Allein in den letzten beiden Jahren konnte das Unternehmen aus dem ... Handelszeitung Online Sem remédio, menina corre risco de morte - May 13, 2008 ...a pequena Alice Dourado de Carvalho teve o tratamento interrompido em abril, quando deixou de ingerir doses diárias do medicamento Miglustat Zavesca, ... A Tarde On Line סל הברי×?ות הב×?: 181 תרופות חדשות - Jan 31, 2005 ...avandia/rossini - טיפול בסוכרת, novonorm - טיפול בסוכרת, zavesca - טיפול בחולי גושה, plavix - טיפול × ×•×’×“ ... NRG מעריב Male contraception: One door opens, another closes - Nov 7, 2006 The latest promising contraceptive that didn't make the leap from mice to men is miglustat (trade name Zavesca) (Human Reproduction, Oct. 25). ... PhysOrg.com Panacos Reports Fourth Quarter and Full Year 2006 Financial Results - Feb 21, 2007 Dr. Lategan was instrumental in the regulatory approvals of several drugs, including TRACLEER, ZAVESCA, and ANGIOMAX and was previously Vice President, ... Genetic Engineering News - Genetic Engineering News (press release) Boston Healthcare Appoints Adam Barak As Vice President Enhancing Its... - Oct 28, 2008 ...reimbursement, and market access strategy for Zavesca, the company's first pharmaceutical launch. In 2002, Mr. Barak established his own consultancy, ... RedOrbit Biotechnology Pioneer Jean-Paul Clozel Named Ernst & Young World … - Jan 6, 2008 ...a chronic, life-threatening disorder which severely compromises the function of the lungs and heart, Zavesca (miglustat), a small-molecule oral therapy ... Ad-Hoc-News - Ad-Hoc-News (Pressemitteilung) Stop That Sperm! A Contraceptive Pill For Men? - Nov 21, 2007 Miglustat, approved under the brand name Zavesca in both the US and the EU for treatment of Gaucher Disease, interferes with sperm development and is ... Pharmalot Welsh Company Goes Green to Find a Therapy for Cancer - Nov 23, 2005 Imino sugars have shown therapeutic potential as drugs for a number of medical uses (the marketed drugs Zavesca and Glyset are imino sugars for example) but ... RedOrbit Actelion's 1st-qtr 2007 loss deepens 179%.(Financial report) - Apr 30, 2007 Income from Zavesca (miglustat), the first oral treatment option for type I Gaucher disease, reached 7.5 million francs vs 5.4 million francs, though it was ... Free with registration - Pharma Marketletter - AccessMyLibrary.com ALSO NOTED: Avastin approval may lower FDA bar; GTX shares … - Feb 25, 2008 Actelion has formally withdrawn its application to the EMEA to extend approval of Zavesca. Release. > The NIH has kicked off a big trial pitting Avastin ... FierceBiotech Male Contraception: One Door Opens, Another Closes - Nov 12, 2006 The latest promising contraceptive that didn't make the leap from mice to men is miglustat (trade name Zavesca) (Human Reproduction, Oct. 25). ... Medical News Today - Medical News Today (press release) Local boy will be special guest of O's - Feb 26, 2007 He does take an experimental drug called Zavesca twice a day. It tastes terrible and can cause tremors and stomach problems. ... Frederick News Post - Frederick News Post (subscription) Grieving parents' thanks to fundraisers - Nov 14, 2008 ...told how a massive fundraising effort from people across Gwent allowed Mr and Mrs Hartland to buy experimental drug Zavesca to treat Amber's condition. ... South Wales Argus Biotech--Big Pharma Collaborations: Modified And - Dec 26, 2005 ...(Belgium) deal covering the Gaucher's SWX:ATLN) disease product Zavesca Cambridge Abbott They reached an agreement Antibody Laboratories regarding ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com OnMedica - News: SIGN guidance on stroke and TIA, and BNF will be … - Dec 22, 2008 ...support in vascular surgery; and Zavesca (miglustat) to treat progressive neurological signs in adults and children with Niemann-Pick type C disease. ... OnMedica Healthcare: Packer Forbes Lands Tracleer UK Promotion - Mar 30, 2005 Sante continues to promote Zavesca, Actelion's product for Gaucher Disease, in the UK (PRWeek, 23 April 2004). Packer Forbes reports to Actelion brand ... RedOrbit Biotech majors face output woes - Apr 11, 2005 ...“However, Genzyme faces loss of market share in Fabry's disease and Gaucher's diseases due to increased competition from OGS/Actelion's Zavesca and ... ICIS Healthcare: Packer Forbes lands Tracleer UK promotion - Mar 25, 2005 Sante continues to promote Zavesca, Actelion's product for Gaucher Disease, in the UK (PRWeek, 23 April 2004). Packer Forbes reports to Actelion brand ... PRWeek UK Parseghian Foundation lauds efforts to cure rare disease - Jun 2, 2006 Zavesca, a drug developed to treat Gaucher disease - a lipid-storage disorder - is shown to slow the progression of NP-C in mice and is in clinical trials ... Tucson Citizen Actelion exceeds its high targets. Company targets turnover of SFR 1... - Feb 25, 2005 Actelions second pharmaceutical, Zavesca for rare metabolic disorders achieved a turnover of SFR 6.1 M in 2004 (SFR 0.7 M in 2003) but remains marginal ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Tracleer (Bosentan) Receives New Indication In Patients With Systemic... - Apr 29, 2008 Actelion markets Tracleer®, an orally available dual endothelin receptor antagonist, for pulmonary arterial hypertension (PAH) and Zavesca®, ... Medical News Today - Medical News Today (press release) Urch Publishes Report on Orphan Drugs in Europe - Jan 5, 2005 ...orphan drugs Aldurazyme, Busilvex, Carbaglu, Fabrazyme, Glivec, Litak, PhotoBarr, Onsenal, Replagal, Somavert, Tracleer, Trisenox, Ventavis and Zavesca. ... prweb.com Success for Swiss biotech firm - Oct 31, 2005 Actelion has two products, Tracleer for pulmonary arterial hypertension, and Zavesca for the rare enzyme-deficiency Gaucher disease. ... Chemistry World FOUNDATION LEADER RECALLS AGONY OF LOSS THREE OF HER … - Aug 8, 2006 Marcia briefly tried the expensive, experimental drug Zavesca. The Parseghians' insurance company paid for it, she said, "without blinking an eye. ... $3.95 - Modesto Bee - NewsBank Actelion recovers from poor first quarter. - Aug 4, 2008 Zavesca (miglustat) was up 23% during the six-month period compared with the first half of 2007 to 19.7 million francs. ... $9.94 - Pharma Marketletter - Alacra Store |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |